Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore

Minipress XL contains prazosin and is primarily used in India for treating hypertension, or high blood pressure, and managing urinary symptoms associated with benign prostatic hyperplasia (BPH), a
condition involving enlargement of the prostate. The acquisition, therefore, strengthens Novartis India’s presence in cardiovascular therapies while also giving it a brand used in the management of BPH.

Minipress XL recorded revenue of Rs 228.6 crore and delivered a compound annual growth rate of 6.3 percent over the past four years, according to IQVIA MAT July 2026 data cited by Novartis India.

Following the approval, Novartis India signed an asset purchase agreement and trademark assignment deeds with the two Pfizer entities. The signing and completion of the transaction took place simultaneously.

Novartis India said the acquisition is not a related-party transaction. Pfizer Inc and Pfizer Products Inc are also unrelated to its promoter, promoter group or group companies.

The deal comes as Pfizer exits the product in India. Pfizer Ltd said in a separate stock exchange filing that it would discontinue the marketing, distribution and sale of Minipress XL with effect from
September 7, following a decision by Pfizer Inc, USA, to discontinue the manufacture of the product.